In Brief: Perrigo
This article was originally published in The Tan Sheet
Executive Summary
Perrigo: Receives FDA go-ahead to manufacture clemastine fumarate tablets 1.34 mg with the agency's approval of an ANDA, the company announced Dec. 5. Perrigo has been selling a store-brand version of Sandoz' Tavist-1 antihistamine with ingredient obtained from an outside supplier. Perrigo also sells a store-brand equivalent of Tavist-D with clemastine fumarate 1.34 mg and phenylpropanolamine hydrochloride 75 mg, extended release, under a licensing agreement with Sandoz ("The Tan Sheet" Sept. 19, 1994, p. 4)...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning